RE:Nailoser, Lithloser, Gojo, Mkryzzzz, jonnyohboy VS logicHere is the answer to point 2. Still waiting after FIVE years. TORONTO, ON / ACCESSWIRE / June 10, 2019 / GeneNews Limited GEN, a life sciences company specializing in blood-based biomarker tests for early cancer detection, announced today that it has signed a Global Licensing and Services Agreement (the "Agreement") with Oncore Pharma, Inc.
According to the Agreement, Oncore Pharma and its partners will commercialize ColonSentry® in all countries other than the Unites States and Canada, under an exclusive license. GeneNews and Oncore Pharma will work together in Canada. The 5-year licensing agreement will initially focus on the Netherlands, Belgium, Luxemburg, Germany, France, Switzerland, Austria, Spain, Monaco, Italy, Portugal, United Kingdom, Ireland, Norway, Sweden, Finland, Denmark, Israel, and the United Arab Emirates as well as Canada. The agreement with Oncore Pharma aims to deploy a total of 1,750,000 tests over the next 5 years.
Under the terms of the agreement, GeneNews will receive a fixed fee per ColonSentry test, a special royalty payment equal to 10% of Oncore's yearly profits and receive one million (1,000,000) shares of Oncore Pharma. The processing of ColonSentry will be done in GeneNews' Richmond, Virginia laboratory.
"We created Oncore Pharma to focus specifically on research, development and commercialization of Oncology products and ColonSentry is exactly the type of diagnostic test the market needs and our customers demand," said Dr. Nadeem Saddiqui, the Chief Scientific Officer and CEO of Oncore Pharma Inc. "We have been researching various diagnostic technologies, and the science behind GeneNews' ColonSentry is extraordinary and ahead of any competitors by far," added Dr. Saddiqui.
"We are delighted to be working with Oncore Pharma and their partners and believe the relationship will help us more speedily reach our short term and long-term objectives" said James Howard-Tripp, Chairman and CEO of GeneNews Limited. "The Oncore Pharma team's experience in bringing products to market, coupled with their scientific knowledge in our space, provides our company with a great advantage," added Mr. Howard-Tripp. "We are to begin immediately".
4real4ever wrote: 1. How many sale of Aristotle?
2. How many sale from Oncore Pharma?
3. Why they do the consolidation 3 year ago?
4. Where is the Large healthcare/firefighters/UPMC/Oncore Pharma/3000 tests month/Bell?
5. How much revenue from ColonSentry + BreastSentry + prostate in 2022, 2023 and 2024
6. Why the share price is ,04 today?
7. Why the OTC listing doesn't change anything on the share price?
8. Why the last 5 Investor Summit doesn't bring money?
9. Why Clarus are gone?
10. Why they done 5-6 PP in the last 3-5 years?
11. 1 million per quarter at least?
12. WHY THERE'RE HALTED??????????????????????????????????????????????
Nailoser and friends =
